Skip to main content

Nucala Disease Interactions

There are 2 disease interactions with Nucala (mepolizumab).


Interleukin inhibitors (applies to Nucala) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors. Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated. Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.


  1. (2009) "Product Information. Stelara (ustekinumab)." Centocor Inc
  2. (2009) "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals
  3. (2014) "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc.
  4. (2015) "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals
  5. (2015) "Product Information. Nucala (mepolizumab)." GlaxoSmithKline
  6. (2016) "Product Information. Cinqair (reslizumab)." Teva Pharmaceuticals USA
  7. (2017) "Product Information. Tremfya (guselkumab)." Janssen Biotech, Inc.
View all 7 references

Mepolizumab (applies to Nucala) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Population pharmacokinetic analyses suggest that mepolizumab clearance was comparable between subjects with creatinine clearance values between 50 and 80 mL/min and patients with normal renal function. There is limited data available in subjects with creatinine clearance values less than 50 mL/min. Caution is recommended if using this agent in these patients. Clinical monitoring of renal function is recommended.


  1. (2015) "Product Information. Nucala (mepolizumab)." GlaxoSmithKline

Nucala drug interactions

There are 7 drug interactions with Nucala (mepolizumab).

Report options

QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.